Immune Design Corp ($IMDZ) reported its net loss and net loss per share for the first quarter of 2017 were $12.6 million and $0.50, respectively, compared to $12.3 million and $0.61, respectively, for the first quarter of 2016. Its revenue for the first quarter of 2017 was $5.5 million, up from $1.9 million for the previous corresponding quarter.
ObsEva ($OBSV) announced that its net loss for the first quarter of 2017 was $15.5 million, or $0.58 per basic and diluted share. As of March 31, 2017, ObsEva had cash and cash equivalents of $104.2 million. The company’s research and development expenses for the quarter were $13.1 million and general and administrative expenses were $2.7 million.